New drug cocktail shows promise for advanced kidney cancer in early trial
NCT ID NCT05030506
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called belzutifan, alone or combined with lenvatinib and pembrolizumab, in 45 Chinese participants with advanced kidney cancer that cannot be removed by surgery. The main goals are to check safety, how the drugs move through the body, and any early signs of tumor shrinkage. It is a first step to see if these combinations are worth testing in larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belzutifan (a drug), lenvatinib (a drug), and pembrolizumab (an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced kidney cancer that combines targeted therapy and immunotherapy.
What could go wrong
This is a very early (Phase 1) study with only 45 participants, focused mainly on safety and dosing. It is too soon to know if the combination will work better than existing treatments, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer hospital-Digestive Oncology ( Site 0001)
Beijing, Beijing Municipality, 100142, China
-
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S
Nanjing, Jiangsu, 210000, China
-
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Urology Surgery Department ( Site 0005)
Guangzhou, Guangdong, 510060, China
-
The Second Affiliated hospital of Zhejiang University school of medicine-Urology ( Site 0007)
Hangzhou, Zhejiang, 310052, China
-
Tianjin Medical University Cancer Institute and Hospital ( Site 0003)
Tianjin, Tianjin Municipality, 300060, China